-

06:16:19 AM

CYTO Stock News

CYTO - Altamira Therapeutics Ltd

05/23/22 8:47 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that Bentrio™ has been approved by the Philippines' Food and Drug Administration (FDA) and is now

RHEA-AI

neutral

05/20/22 9:00 AM

Nasdaq : CYTO

clinical triallow float

Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing

RHEA-AI

neutral

05/19/22 9:00 AM

Nasdaq : CYTO

conferenceslow float

Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it is scheduled to present virtually at the H.C. Wainwright Global Investment Conference, being

RHEA-AI

neutral

05/18/22 8:47 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Issues Shareholder Letter

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical

RHEA-AI

neutral

05/05/22 8:47 AM

Nasdaq : CYTO

covid-19low float

Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics

RHEA-AI

neutral

04/19/22 9:00 AM

Nasdaq : CYTO

covid-19low float

Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that that it has reached the midpoint for enrollment in its COVAMID clinical investigation of its

RHEA-AI

neutral

04/12/22 7:30 AM

Nasdaq : CYTO

earningslow float

Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results

SemaPhore™ platform for extrahepatic RNA deliver Established new business unit, OTC Consumer Health, to support global commercialization of Bentrio nasal

RHEA-AI

neutral

04/11/22 8:47 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant

Safety of Bentrio(TM) for Delta Variant Prophylactic treatment of human nasal mucosa with Bentrio™ was reported to significantly reduce the viral titer vs. controls over 4 days, reaching a maximum reduction of 99% with the wild-type SARS-CoV-2 variant and more

RHEA-AI

neutral

04/04/22 8:47 AM

Nasdaq : CYTO

earningslow float

Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it will hold an investor call on Tuesday, April 12, 2022, 8:00 a.m. ET to discuss its full-year 2021

RHEA-AI

neutral

03/15/22 9:00 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced completion of patient enrollment in its Bentrio™ trial in house dust mite ("HDM") allergic rhinitis.

RHEA-AI

neutral

CYTO Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttp://www.aurismedical.com/
CeoThomas Meyer
Security nameAltamira Therapeutics Ltd
Issue typecs
SectorManufacturing
Sic code2834
Employees9
AddressBahnhofstrasse 21
StateZug
CityZug
Zip6300
CountrySwitzerland
Phone41417297194

About Altamira Therapeutics Ltd

Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.'